AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 201 min read$SKYE

Schwab Andrew J. sold $140K of SKYE (indirect holdings)

Schwab Andrew J. sold 375,840 indirectly-held shares of Skye Bioscience, Inc. (SKYE) at an average of $0.37 ($0.32–$0.38, $0.14M total) across 9 trades over 2026-08-18 to 2026-08-20.

Original reporting
SEC EDGAR · Schwab Andrew J.
Published Aug 20, 2026, 9:59 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 20, 2026, 10:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$SKYE
Bearish
medium confidence
Mentioned
$SKYE
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SKYEBearishLow
01

Why it matters

The disclosed sale provides fresh data on insider sentiment for SKYE.

02

Market read

First-report insider sale; modest size but notable due to insider's large ownership stake.

03

What to watch

No new corporate developments accompany the filing; price may remain stable.

Relevance 4/10Novelty 4/10Timing: filed today

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$SKYEBearishMedium confidence
Context

Director Andrew J. Schwab sold 375,840 shares for $140K, reducing his indirect holdings to 7.85M shares.

Expected impact

Possible modest downside pressure over the next few days.

Evidence & confidence

The sale size is modest ($140K) but the insider holds a significant stake; market may interpret the sale as a negative signal.

Market effects

Sector

Minimal impact on the biotech sector; isolated insider transaction.

Regional

Negligible effect on broader market.

Global

None

Counterpoint

What could challenge this read

The sale could be routine liquidity management, not a negative signal.

Key entities

  • Company
    Skye Bioscience, Inc.

    Biotech firm listed on Nasdaq under ticker SKYE.

  • Insider
    Andrew J. Schwab

    Director and 10% owner of SKYE.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

SKYE insider trading history →

Related articles

AUG 17
$SKYEMedAI 8/10

Skye To Acquire Redx; $125M Financing Secures Path To RXC008 Phase 2 Trial; Stock Up

Skye Bioscience (SKYE) will acquire Redx Pharma via a scheme of arrangement, creating Nasdaq-listed Fibrx Therapeutics led by Redx management. The lead asset is RXC008 for fibrostenotic Crohn’s, with FDA Fast Track and Phase 2 topline data expected in H2 2028. Financing totals $125M, including a $68M PIPE and $36M Series A, funding operations into 2029. SKYE closed at $0.50.

rttnews.com4 min
AUG 14
$SKYEHighAI 9/10

Skye Bioscience, Inc.: Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings

Skye Bioscience (Nasdaq: SKYE) will acquire privately held Redx Pharma via a UK scheme of arrangement, forming Fibrx Therapeutics that will trade on Nasdaq. The deal includes about $125 million in committed financings, including a ~$68 million PIPE and a $36 million Series A. Funds are expected to support RXC008 Phase 2 through 2029, with topline data in H2 2028.

finanznachrichten.de4 min